Prognostic Value of Metabolic Response Measured by FDG-PET-CT in Patients with Breast Cancer Liver Metastasis Treated with Stereotactic Body Radiotherapy

Abstract

OBJECTIVETo investigate the impact of metabolic response measured by 18-fluorodeoxyglucose positron emissiontomography and computed tomography (FDG-PET-CT) in patients with breast cancer liver metastasis(BCLM) treated with stereotactic body radiotherapy (SBRT).METHODSThe medical records of 17 patients with BCLM treated with SBRT between March 2013 and October 2017were investigated retrospectively. Patients received SBRT for their liver metastasis, and thereafter, a secondFDG-PET-CT was performed for response assessment in a median of 4.1 (2.2–8.2) months. A total of 54Gy in three fractions were delivered to liver metastatic lesions. The standardized uptake value (SUV) andsurvival rates were evaluated.RESULTSAfter a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between preand post-SBRT SUVs (p